Keysight Technologies Inc Valuation – April 2019 #KEYS

Company Profile (excerpt from Reuters): Keysight Technologies, Inc. (Keysight), incorporated on December 6, 2013, is a measurement company engaged in providing electronic design and test solutions to communications and electronics industries. The Company provides electronic design and test instruments and systems and related software, software design tools and related services that are used in the design, development, manufacture, installation, deployment and operation of electronics equipment. The Company operates through three segments: Communications Solutions Group (CSG), Electronic Industrial Solutions Group (EISG) and Services Solutions Group (SSG). The CSG and EISG segments provide electronic design and test software, instruments, and systems used in the simulation, design, validation, manufacturing, installation and optimization of electronic equipment. The SSG segment provides integrated service solutions, including repair and calibration services, professional services and remanufactured equipment.


Downloadable PDF version of this valuation:

ModernGraham Valuation of KEYS – April 2019

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

What kind of Intelligent Investor are you?


Defensive Investor; must pass 6 out of the following 7 tests.
1. Adequate Size of the Enterprise Market Cap > $2Bil $16,693,423,773 Pass
2. Sufficiently Strong Financial Condition Current Ratio > 2 1.82 Fail
3. Earnings Stability Positive EPS for 10 years prior Fail
4. Dividend Record Dividend Payments for 10 years prior Fail
5. Earnings Growth Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end 17200.00% Pass
6. Moderate PEmg Ratio PEmg < 20 43.15 Fail
7. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 6.35 Fail
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.
1. Sufficiently Strong Financial Condition Current Ratio > 1.5 1.82 Pass
2. Sufficiently Strong Financial Condition Debt to NCA < 1.1 1.13 Fail
3. Earnings Stability Positive EPS for 5 years prior Pass
4. Dividend Record Currently Pays Dividend Fail
5. Earnings Growth EPSmg greater than 5 years ago Pass


Stage 2: Determination of Intrinsic Value

EPSmg $2.06
MG Growth Estimate 3.98%
MG Value $33.86
Opinion Overvalued
MG Grade F
MG Value based on 3% Growth $29.84
MG Value based on 0% Growth $17.49
Market Implied Growth Rate 17.32%
Current Price $88.80
% of Intrinsic Value 262.22%

Keysight Technologies Inc does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings stability over the last ten years, and the poor dividend history, and the high PEmg and PB ratios. The Enterprising Investor has concerns regarding the level of debt relative to the net current assets, and the lack of dividends. As a result, all value investors following the ModernGraham approach should explore other opportunities at this time or proceed cautiously with a speculative attitude.

As for a valuation, the company appears to be Overvalued after growing its EPSmg (normalized earnings) from $1.63 in 2015 to an estimated $2.06 for 2019. This level of demonstrated earnings growth does not support the market’s implied estimate of 17.32% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on the Benjamin Graham value investing formula, returns an estimate of intrinsic value below the price.

At the time of valuation, further research into Keysight Technologies Inc revealed the company was trading above its Graham Number of $33.26. The company does not pay a dividend. Its PEmg (price over earnings per share – ModernGraham) was 43.15, which was above the industry average of 35.4. Finally, the company was trading above its Net Current Asset Value (NCAV) of $-4.08.

Keysight Technologies Inc scores quite poorly in the ModernGraham grading system, with an overall grade of F.

Stage 3: Information for Further Research

Net Current Asset Value (NCAV) -$4.08
Graham Number $33.26
PEmg 43.15
Current Ratio 1.82
PB Ratio 6.35
Current Dividend $0.00
Dividend Yield 0.00%
Number of Consecutive Years of Dividend Growth 0

Useful Links:



ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Balance Sheet Information 1/1/2019
Total Current Assets $2,544,000,000
Total Current Liabilities $1,400,000,000
Long-Term Debt $1,291,000,000
Total Assets $5,978,000,000
Intangible Assets $1,775,000,000
Total Liabilities $3,320,000,000
Shares Outstanding (Diluted Average) 190,000,000

Earnings Per Share History

EPS History
Next Fiscal Year Estimate $3.77
Oct2018 $0.86
Oct2017 $0.56
Oct2016 $1.95
Oct2015 $3.00
Oct2014 $2.35

Earnings Per Share – ModernGraham History

EPSmg History
Next Fiscal Year Estimate $2.06
Oct2018 $1.38
Oct2017 $1.62
Oct2016 $1.92
Oct2015 $1.63
Oct2014 $0.78

Recommended Reading:

Other ModernGraham posts about the company

Keysight Technologies Inc Valuation – August 2018 $KEYS
Keysight Technologies Inc Valuation – Initial Coverage $KEYS

Other ModernGraham posts about related companies

Skyworks Solutions Inc Valuation – March 2019 #SWKS
Garmin Ltd Valuation – March 2019 #GRMN
Hewlett Packard Enterprise Co Valuation – March 2019 #HPE
Fortive Corp Valuation – March 2019 #FTV
Analog Devices Inc Valuation – March 2019 #ADI
IPG Photonics Corp Valuation – March 2019 #IPGP
Micron Technology Inc Valuation – March 2019 #MU
Amphenol Corp Valuation – March 2019 #APH
Xilinx Inc Valuation – March 2019 #XLNX
Western Digital Corp Valuation – March 2019 #WDC


The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.

Tamoxifen “is the most powerful antiestrogen drug in terms of effectiveness of all that is available today in the sports pharmacology market.Tamoxifen is the most popular brand name for this drug. It is also on sale under the name Nolvadex (although it is much less common).

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.